Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer

Background: This phase II study describes the efficacy and safety of combination chemotherapy of 5-fluorouracil (5-FU), low-dose leucovorin, and oxaliplatin (FLOX regimen) for pretreated advanced gastric cancer. Patients and methods: Patients who had been previously treated with greater than or equal to one regimen were enrolled. Patients received an oxaliplatin 75 mg/m 2 on day 1, 5-FU 1000 mg/m 2 on days 1-3, and leucovorin 20 mg/m 2 on days 1-3, every 3 weeks. The primary end point was overall survival (OS). Results: Among the 52 patients enrolled, 26 patients were treated as second line, and the remaining 26 patients were enrolled as third- or fourth line. A total of 203 cycles of chemotherapy were administered with the median being three cycles (range 1-15) per patient. The median OS was 6.6 months [95% confidence interval (Cl) 4.5-8.8] and the median progression-free survival was 2.5 months (95% Cl 1.9-3.0). The response rate was 4% (95% Cl 0-9%), and the disease control rate was 48% (95% Cl 34-62%). The most common toxic effects of grade 3/4 were neutropenia (16%) and vomiting (6%). Conclusions: The FLOX regimen showed modest activity as a salvage treatment in pretreated advanced gastric cancer with a favorable compliance.